Innovative Tech Development Rapid is actively developing cutting-edge cloud-based SPECT reconstruction platforms, backed by a $2 million NIH grant, presenting opportunities for partnership or integration with organizations seeking advanced imaging solutions.

Specialized Clinical Services With expertise in protocol development and FDA-ready reporting for multi-center radiopharmaceutical trials, Rapid can offer tailored consulting services to biotech and pharmaceutical companies entering or expanding in radiopharmaceutical therapeutic and diagnostic markets.

Growing Industry Presence Operating within the biotechnology research sector with a niche focus on dosimetry and imaging, Rapid’s developments position it as a promising collaborator with medical device firms and clinical research organizations.

Funding and Innovation The recent NIH grant underscores the company's focus on innovative solutions, making it especially attractive to funders and partners invested in advancing radiopharmaceutical therapy technologies.

Market Opportunity Straddling the $1M to $10M revenue range with a small team, Rapid offers a flexible partner profile for organizations looking for specialized expertise in radiopharmaceutical imaging and dosimetry services, with potential for scalability.